Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
OBIO Orchestra BioMed Holdings Inc
- Stocks
- Healthcare
- NASDAQ: OBIO
Price (delayed)
$2.9
Market cap
$111.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.78
Enterprise value
$109.2M
Highlights
The company's gross profit rose by 31% YoY and by 10% QoQ
Orchestra BioMed Holdings's revenue has increased by 30% YoY and by 9% QoQ
The equity has plunged by 71% YoY and by 49% from the previous quarter
Orchestra BioMed Holdings's quick ratio has shrunk by 55% YoY and by 22% QoQ
Key stats
What are the main financial stats of OBIO
Market
Valuations
Earnings
Shares outstanding
38.31M
Market cap
$111.11M
Enterprise value
$109.2M
Price to earnings (P/E)
N/A
Price to book (P/B)
6.59
Price to sales (P/S)
38.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
37.84
Revenue
$2.89M
Gross profit
$2.67M
Operating income
-$68.8M
Net income
-$66.32M
EBIT
-$66.32M
EBITDA
-$65.25M
Free cash flow
-$54.45M
Per share
Balance sheet
Liquidity
EPS
-$1.78
EPS diluted
-$1.78
Free cash flow per share
-$1.42
Book value per share
$0.44
Revenue per share
$0.08
TBVPS
$1.54
Total assets
$59.05M
Total liabilities
$42.19M
Debt
$16.44M
Equity
$16.86M
Working capital
$36.41M
Debt to equity
0.98
Current ratio
3.35
Quick ratio
3.23
Net debt/EBITDA
0.03
Margins
Efficiency
Dividend
EBITDA margin
-2,261%
Gross margin
92.6%
Net margin
-2,297.9%
Operating margin
-2,383.9%
Return on assets
-93.8%
Return on equity
-189.3%
Return on invested capital
-159%
Return on capital employed
-152.2%
Return on sales
-2,297.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OBIO stock price
How has the Orchestra BioMed Holdings stock price performed over time
Intraday
0.35%
1 week
9.43%
1 month
1.4%
1 year
-37.23%
YTD
-27.5%
QTD
-32.24%
Financial performance
How have Orchestra BioMed Holdings's revenue and profit performed over time
Revenue
$2.89M
Gross profit
$2.67M
Operating income
-$68.8M
Net income
-$66.32M
Gross margin
92.6%
Net margin
-2,297.9%
The company's gross profit rose by 31% YoY and by 10% QoQ
Orchestra BioMed Holdings's revenue has increased by 30% YoY and by 9% QoQ
OBIO's net income is down by 28% YoY and by 9% QoQ
The operating income has declined by 27% year-on-year and by 7% since the previous quarter
Price vs fundamentals
How does OBIO's price correlate with its fundamentals
Growth
What is Orchestra BioMed Holdings's growth rate over time
Valuation
What is Orchestra BioMed Holdings stock price valuation
P/E
N/A
P/B
6.59
P/S
38.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
37.84
Orchestra BioMed Holdings's EPS has decreased by 20% YoY and by 7% from the previous quarter
The equity has plunged by 71% YoY and by 49% from the previous quarter
The price to book (P/B) is 4.6% higher than the last 4 quarters average of 6.3
OBIO's price to sales (P/S) is 53% less than its last 4 quarters average of 81.5
Orchestra BioMed Holdings's revenue has increased by 30% YoY and by 9% QoQ
Efficiency
How efficient is Orchestra BioMed Holdings business performance
OBIO's ROE has dropped by 170% year-on-year and by 40% since the previous quarter
Orchestra BioMed Holdings's return on invested capital has shrunk by 132% YoY and by 14% QoQ
The company's return on assets has shrunk by 91% YoY and by 18% QoQ
Dividends
What is OBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OBIO.
Financial health
How did Orchestra BioMed Holdings financials performed over time
The company's total assets is 40% higher than its total liabilities
OBIO's total liabilities has soared by 66% YoY but it is down by 2.4% QoQ
Orchestra BioMed Holdings's quick ratio has shrunk by 55% YoY and by 22% QoQ
Orchestra BioMed Holdings's debt is 2.5% less than its equity
The debt to equity has soared by 96% QoQ
The equity has plunged by 71% YoY and by 49% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.